SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to a recent FDA filing for ANKTIVA and the strategic securing of the Tokyo-172 BCG strain, moves the community believes effectively derisk the company's path to broader bladder cancer market dominance. While the stock faces volatility from ongoing institutional short positions, retail investors are actively discussing these developments as a potential turning point that could force a significant short squeeze.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Investors are actively debating the trajectory of long-term bonds as rising yields and persistent inflation fears fuel speculation about potential Federal Reserve rate hikes. The community remains deeply divided, with some betting on a continued selloff in TLT while others view the current price levels as a tactical buying opportunity amidst broader market uncertainty.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing intense volatility as investors weigh the impact of surging bond yields and a strengthening dollar against broader inflationary pressures. The community is sharply divided, with some traders actively shorting the metal amid signs of a technical breakdown, while others view the pullback as a long-term buying opportunity driven by persistent industrial demand.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as investor sentiment surges following an earnings report that featured a strong revenue beat and upwardly revised full-year guidance, with the community highlighting the brand's rapid store expansion and traffic growth. While some investors remain skeptical about the stock's high valuation multiples, bullish participants are actively discussing its potential to become the next dominant leader in the fast-casual sector, citing a debt-free balance sheet and strong customer loyalty as key long-term advantages.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is facing a sharp selloff and hitting 52-week lows as the CEO cited concerns over consumers feeling stretched on discretionary spending, alongside broader macroeconomic pressures like inflation. While the community is actively debating the company's resilience and potential as a long-term value play, many are skeptical about the stock's persistent downward momentum and are questioning the timing of a potential reversal.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the central focus of market conversation as investors brace for the company's upcoming earnings report, which many view as a critical bellwether for the sustainability of the broader AI-driven market rally. The community is deeply divided, with bulls anticipating a blowout quarter that could reignite risk appetite, while bears are expressing concern over high valuations and the potential for a "sell-the-news" reaction regardless of the results.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as the stock hits fresh record highs, driven by strong operational performance and growing institutional confidence. The community is actively debating the potential for a future stock split or special dividend, while simultaneously monitoring the stock's defensive leadership amidst broader market rotation.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is currently trending due to intense volatility driven by news of a major labor strike at Samsung Electronics, which has raised concerns over regional semiconductor output and AI hardware supply chains. The community is actively debating the potential for a deeper market correction in the KOSPI index, with many investors weighing the long-term AI-driven memory demand against the immediate risks of margin calls and forced liquidation.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is trending as it prepares to lead the massive SpaceX IPO, which the community is debating alongside the bank's active involvement in the AI sector and institutional credit markets. Investors are also closely monitoring how the firm's leadership in high-stakes dealmaking and its ongoing strategic pivots are positioning the stock ahead of upcoming quarterly earnings.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors weigh the potential impacts of a new fintech executive order against ongoing macro headwinds, such as elevated interest rate concerns and a difficult yield environment. While the community remains deeply polarized, bulls are pointing to long-term fundamentals and recent institutional buying as a buying opportunity, whereas bears are focused on the stock's poor technical performance and the lack of immediate catalysts to reverse the current downtrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray [&#8230;]

<ul class="summary-bullets"><li>The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026.</li><li>Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression.</li><li>Allucent will provide end-to-end support for the clinical trial, including execution and data management.</li></ul>Shares of Quantum BioPharma (QNTM) surged 15% in pre-market trading on Monday after the biotech firm signed a binding agreement with Allucent to support a planned Phase 2 trial of its Lucid-MS therapy for multiple sclerosis.The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026, Quantum BioPharma said.Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression. Allucent will provide end-to-end support for the clinical trial, including execution and data management.“This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration,” said Andrzej Chruscinski, VP, Scientific and Clinical Affairs at Quantum BioPharma.&nbsp;&nbsp;<h2 class="st-heading-2">Funding Update</h2>Earlier this month, Quantum BioPharma completed oral dosing of Lucid-21-302 (Lucid-MS) in both its 180-day toxicity and toxicokinetic studies, marking an important step toward filing an Investigational New Drug (IND) application with the U.S. FDA. The company is focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol-related disorders, with multiple drug candidates in its pipeline.Alongside clinical progress, Quantum BioPharma also strengthened its financial position by closing the first tranche of a previously announced offering, raising $3.75 million through the issuance of 3,750 debenture units.&nbsp;Additionally, the company settled about $1.12 million in debt by issuing over 370,000 Class B shares to certain creditors and insiders, helping improve its balance sheet.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/QNTM">QNTM</a> remained 'bullish' over the past 24 hours, amid 'extremely high' message volumes.One user said the company's market cap should be "north of $100 million" following the developments.<stembedurl>https://stocktwits.com/TAGtrade/message/648919385</stembedurl>Year-to-date, the stock has declined 30%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did QNTM Stock Pop In Pre-Market Today?

The biotech company signed a binding agreement with Allucent to support a planned Phase 2 trial to treat multiple sclerosis.

Equity

Quantum BioPharma Targets MS Progression with Novel Demyelination Therapy in Phase 2 Push

Quantum BioPharma (NASDAQ:QNTM) is taking a meaningful step forward in its clinical ambitions, signing a binding letter of intent with Allucent to advance its lead multiple sclerosis candidate, Lucid-21-302 (Lucid-MS), into a Phase 2 trial. The agreement signals more than operational progress, it reflects a broader push to bring differentiated, next-generation therapies into a market that remains heavily underserved despite decades of innovation.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM INVESTOR ALERT: Pomerantz Law Firm...

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM CONTACT: INVESTOR ALERT...

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to...

<ul class="summary-bullets"><li>The stock surged as Canadian media spotlight renewed scrutiny of Quantum’s alleged market-spoofing case.</li><li>The coverage drew fresh attention to the company’s $700 million federal lawsuit over price manipulation.</li><li>Lucid-MS’s Phase 1 safety data in August supported advancement toward patient trials.</li></ul>Quantum BioPharma shares surged on Tuesday after a Canadian media investigation spotlighted the company’s claims that years of alleged stock spoofing depressed its valuation and harmed its lead multiple-sclerosis program. The renewed attention came as CTV’s investigative flagship W5 began airing a three-part series examining Quantum’s lawsuit seeking more than $700 million in damages.The stock closed up 30% at $8.04 on Tuesday and added another 5% in after-hours trading.<h2 class="st-heading-2">CTV Investigation Highlights Company’s Manipulation Claims</h2>The W5 series focuses on Quantum’s allegation that its shares were repeatedly manipulated through illegal “stock spoofing” conducted by CIBC World Markets, RBC Dominion Securities and others from January 2020 to August 2024. The practice, which involves placing and canceling non-bona fide buy and sell orders, is prohibited in both Canada and the U.S.W5 reporter Jon Woodward previewed the first installment in an article titled “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?” The program began airing Part One on Tuesday, drawing renewed attention to Quantum’s claims and its ongoing legal fight.<h2 class="st-heading-2">Quantum Alleges Banks Used Spoofing To Drive Shares Lower</h2>Quantum filed its initial complaint in October 2024 in the U.S. District Court for the Southern District of New York and amended it in May after defendants moved to dismiss. The company alleges violations of the Securities Exchange Act, asserting that hundreds of spoofing events artificially pushed its stock lower.Quantum said its shares traded above $460 on a split-adjusted basis in early 2020 with a market cap near $1 billion, compared with $7.55 by October 2024. The firm also maintains that additional banks or brokers may have been involved, but said it will not identify them until it has gathered sufficient evidence.The law firms Christian Attar and Freedman Normand Friedland LLP are pursuing the case on a contingency basis after conducting an extensive investigation with industry experts.<h2 class="st-heading-2">Progress In Lucid-MS Program&nbsp;</h2>In August, Quantum BioPharma reported that its lead multiple sclerosis candidate, Lucid-MS, passed a key safety hurdle after a Phase 1 multiple-ascending-dose study found no safety or tolerability issues in healthy volunteers. The company said the clinical study report supported its plans to advance into patient efficacy trials.Lucid-MS is a first-in-class, non-immunomodulatory neuroprotective compound designed to prevent or reverse myelin degradation, based on preclinical data.&nbsp;<h2 class="st-heading-2">Stocktwits Users Eye A Sharp Rebound</h2>On Stocktwits, retail sentiment for Quantum BioPharma was ‘extremely bullish’ amid a 3,400% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:971/141;" src="https://news.stocktwits-cdn.com/qntm_ss_png_e73bb7bac7.webp" alt="qntm ss.png" width="971" height="141"><figcaption>QNTM sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One user predicted, “shorts will be covering tomorrow due to thanksgiving. Should see $18 soon.”<stembedurl>https://stocktwits.com/James9921/message/637453956</stembedurl>Another user said, “this one has been absolutely wrecked here but historically when the stocks this low it sees a violent move up. Watching closely here.”<stembedurl>https://stocktwits.com/makedatbread88/message/637220177</stembedurl><a href="https://stocktwits.com/symbol/QNTM">Quantum BioPharma’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Quantum BioPharma’s stock (QNTM) has more than doubled so far in 2025. (Photo credit: Getty Images)

Quantum BioPharma Stock Rockets As Media Probe Shines Light On Spoofing Allegations Linked To Its $700M Lawsuit

Lucid-MS’s Phase 1 safety data in August supported advancement toward patient trials.

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

QNTM
Quantum BioPharma Ltd

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest QNTM News

QNTMQuantum BioPharma Ltd